|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
JPS63203626A
(ja)
*
|
1987-02-19 |
1988-08-23 |
Ajinomoto Co Inc |
免疫抑制剤
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
ATE135397T1
(de)
|
1988-09-23 |
1996-03-15 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
SE509359C2
(sv)
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5891693A
(en)
|
1990-01-25 |
1999-04-06 |
Alusuisse Holdings A.G. |
Recombinant DNA methods vectors and host cells
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
|
US5264365A
(en)
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
DK0752248T3
(da)
|
1992-11-13 |
2000-11-13 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5639635A
(en)
|
1994-11-03 |
1997-06-17 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
AU2660397A
(en)
|
1996-04-05 |
1997-10-29 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
DE19751857A1
(de)
|
1997-11-22 |
1999-05-27 |
Kronos Titan Gmbh |
Phosphonatosiloxanbehandelte anorganische Partikel
|
|
ES2590912T3
(es)
|
1997-12-08 |
2016-11-24 |
Merck Patent Gmbh |
Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
MXPA02001417A
(es)
*
|
1999-08-09 |
2002-08-12 |
Lexigen Pharm Corp |
Complejos multiples de citosina-anticuerpo.
|
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING A POLYPEPTIDE
|
|
EP1240337B1
(en)
|
1999-12-24 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
EP2213743A1
(en)
|
2000-04-12 |
2010-08-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
DE10045592A1
(de)
*
|
2000-09-15 |
2002-03-28 |
Klaus Pfizenmaier |
Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
CA2430013C
(en)
|
2000-11-30 |
2011-11-22 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
US6942853B2
(en)
*
|
2001-01-09 |
2005-09-13 |
Queen Mary And Westfield College |
Latent fusion protein
|
|
AU2002335930B2
(en)
|
2001-03-09 |
2005-07-28 |
Morphosys Ag |
Serum albumin binding moieties
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
WO2003059934A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
CA2481925A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for patients having human fc.gamma.riiia
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
EP1500400A4
(en)
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
CN1703423A
(zh)
*
|
2002-10-14 |
2005-11-30 |
豪夫迈－罗氏公司 |
Il－15拮抗剂
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2004041863A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against interferon- gamma and uses therefor
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
|
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
US20090208500A1
(en)
|
2005-06-03 |
2009-08-20 |
Genentech, Inc. |
Method of producing antibodies with improved function
|
|
US8741832B2
(en)
|
2005-06-10 |
2014-06-03 |
Albert Einstein College Of Medicine Of Yeshiva University |
Pegylated albumin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
SI2173890T1
(sl)
|
2007-06-21 |
2011-06-30 |
Univ Muenchen Tech |
Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
|
|
EP2171052B1
(en)
|
2007-07-12 |
2014-08-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
|
|
US8592555B2
(en)
|
2008-08-11 |
2013-11-26 |
Emd Millipore Corporation |
Immunoglobulin-binding proteins with improved specificity
|
|
AU2010215761B2
(en)
*
|
2009-02-23 |
2017-04-06 |
Cytomx Therapeutics, Inc |
Proproteins and methods of use thereof
|
|
ES2598005T3
(es)
|
2009-08-14 |
2017-01-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
|
|
AU2011217728B2
(en)
*
|
2010-02-17 |
2013-03-14 |
Csl Limited |
Compositions and methods for targeting type 1 interferon producing cells
|
|
EP2553101A4
(en)
*
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
EP2556087A1
(en)
|
2010-04-09 |
2013-02-13 |
Novozymes Biopharma DK A/S |
Albumin derivatives and variants
|
|
US9221882B2
(en)
|
2010-05-21 |
2015-12-29 |
Technische Universitat Munchen |
Biosynthetic proline/alanine random coil polypeptides and their uses
|
|
AU2012202125B2
(en)
*
|
2010-08-17 |
2015-03-19 |
Csl Limited |
Humanized Anti-Interleukin 3 Receptor Alpha Chain Antibodies
|
|
US8507222B2
(en)
|
2010-09-21 |
2013-08-13 |
Altor Bioscience Corporation |
Multimeric IL-15 soluble fusion molecules and methods of making and using same
|
|
US20130225496A1
(en)
|
2010-11-01 |
2013-08-29 |
Novozymes Biopharma Dk A/S |
Albumin Variants
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
ES2623912T3
(es)
|
2010-12-23 |
2017-07-12 |
Janssen Biotech, Inc. |
Mutantes FC de anticuerpo activo resistente a proteasa
|
|
SG192673A1
(en)
*
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
CA2878626A1
(en)
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CA2882173C
(en)
|
2012-08-23 |
2020-08-04 |
Lee Tech Llc |
A method of and system for producing oil and valuable byproducts from grains in dry milling systems with a back-end dewater milling unit
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US20140308285A1
(en)
*
|
2013-03-15 |
2014-10-16 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
US9926245B2
(en)
|
2013-09-30 |
2018-03-27 |
Pioneer Energy |
Fuels and chemicals from lower alkanes
|
|
RU2689717C2
(ru)
*
|
2014-01-08 |
2019-05-28 |
Шанхай Хэнжуй Фармасьютикал Ко., Лтд. |
Гетеродимерный белок il-15 и его применения
|
|
WO2016060996A2
(en)
|
2014-10-14 |
2016-04-21 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
WO2016130451A1
(en)
|
2015-02-09 |
2016-08-18 |
Dnx Biotech, Llc |
Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
EP3274459A4
(en)
|
2015-03-27 |
2018-08-22 |
The University of Queensland |
Platform for non-natural amino acid incorporation into proteins
|
|
US20160362469A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
EP4092045A1
(en)
|
2016-05-16 |
2022-11-23 |
Checkmab S.R.L. |
Markers selectively deregulated in tumor-infiltrating regulatory t cells
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
WO2019129053A1
(zh)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
CN108218993B
(zh)
|
2018-01-05 |
2020-11-17 |
阿思科力(苏州)生物科技有限公司 |
一种以robo1为靶点的双特异性抗体及其制备和应用
|
|
TW201938196A
(zh)
|
2018-01-18 |
2019-10-01 |
美商南特生物科學股份有限公司 |
融合蛋白擴展
|
|
CN112004547A
(zh)
|
2018-02-26 |
2020-11-27 |
新索思股份有限公司 |
Il-15缀合物及其用途
|
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
|
EP3762406A2
(en)
|
2018-03-09 |
2021-01-13 |
Askgene Pharma, Inc. |
Cytokine prodrugs
|
|
KR20210005872A
(ko)
|
2018-03-28 |
2021-01-15 |
오리오니스 바이오사이언시즈 인코포레이티드 |
이작용성 단백질 및 이의 작제물
|
|
CU24554B1
(es)
|
2018-05-07 |
2021-11-04 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
AU2019288484B2
(en)
|
2018-06-22 |
2024-06-20 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
EP3810171B1
(en)
|
2018-06-22 |
2025-07-09 |
Cugene Inc. |
Novel interleukin-15 (1l-15) fusion proteins and uses thereof
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
CN112996805A
(zh)
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
SG11202104136YA
(en)
|
2018-10-23 |
2021-05-28 |
Dragonfly Therapeutics Inc |
Heterodimeric fc-fused proteins
|
|
WO2020123980A1
(en)
|
2018-12-14 |
2020-06-18 |
Proviva Therapeutics (Hong Kong) Limited |
Il-15 compositions and methods of use thereof
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
WO2021016599A1
(en)
|
2019-07-25 |
2021-01-28 |
Trutino Biosciences Inc |
Il-2 cytokine prodrugs comprising a cleavable linker
|
|
CA3148505A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
US20220289822A1
(en)
|
2019-08-21 |
2022-09-15 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US20210061871A1
(en)
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified N-810 and Methods Therefor
|
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
MX2022007202A
(es)
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
JP7807076B2
(ja)
|
2019-12-13 |
2026-01-27 |
キュージーン インコーポレイテッド |
新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
|
|
WO2021142476A1
(en)
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
US12589112B2
(en)
|
2020-01-22 |
2026-03-31 |
City Of Hope |
Oncolytic virus compositions including IL-15 complex and methods for the treatment of cancer
|
|
EP4126246A4
(en)
|
2020-04-01 |
2024-05-15 |
Xilio Development, Inc. |
MASKED IL-15 CYTOKINE AND THEIR DECOMPOSITION PRODUCTS
|
|
TW202204388A
(zh)
|
2020-04-01 |
2022-02-01 |
美商艾希利歐發展股份有限公司 |
經遮蔽之il-2細胞激素及其裂解產物
|
|
JP7771076B2
(ja)
|
2020-04-01 |
2025-11-17 |
エクシリオ デベロップメント， インコーポレイテッド |
マスクされたｉｌ－１２サイトカイン及びその切断産物
|
|
MX2022013112A
(es)
|
2020-04-22 |
2023-01-16 |
Dragonfly Therapeutics Inc |
Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
|
|
WO2022115865A2
(en)
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|